Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
?16.19
 
WKN: A2N7N2 / Symbol: ARAV / Name: Aravive / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Aravive, Inc. Stock

The community is currently still undecided about Aravive, Inc. with 1 Buy predictions and 0 Sell predictions.
With a target price of 16 € there is potential for a 49130.77% increase which would mean more than doubling the current price of 0.03 € for Aravive, Inc..
So far the community has only identified positive things for Aravive, Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Aravive, Inc. in the next few years

Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Aravive, Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Aravive, Inc. - - - - - - -
Ardelyx Inc. 0.910% -2.116% -15.296% 40.514% 4.048% -12.204% -
Salarius Pharmaceuticals Inc. -3.170% 2.315% -15.000% -67.971% -20.360% -98.187% -99.994%
Brainstorm Cell 1.170% -1.874% -1.485% -81.975% 114.440% -80.717% -

Comments

Prediction Buy
Perf. (%) -26.25%
Target price 1.070
Change
Ends at 18.11.23

Target price set to 1.07
Show more

Prediction Buy
Perf. (%) -96.28%
Target price 16.191
Change
Ends at 21.07.24

Aravive, Inc. (NASDAQ: ARAV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
Ratings data for ARAV provided by MarketBeat
Show more